CLINICAL TRIAL / NCT05399498

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

  • Interventional
  • Recruiting
  • NCT05399498

Contact Information

  • Malcom Mciver

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).